Xin Hui Chan
Xin Hui Chan
BMBCh MA MSc DPhil MRCP DTM&H DipRCPath
NIHR Academic Clinical Lecturer in Infectious Diseases
- Honorary Specialty Registrar in Infectious Diseases and General Internal Medicine
CLINICAL THERAPEUTICS FOR EMERGING INFECTIOUS DISEASES
Dr Xin Hui Chan is an NIHR Academic Clinical Lecturer in Infectious Diseases at the University of Oxford and an Honorary Specialty Registrar in Infectious Diseases and General Internal Medicine (post-CCT) at Oxford University Hospitals. Her current research focuses on accelerating the equitable development of clinical therapeutics for high-threat and emerging infectious diseases such as Nipah and dengue.
She leads a programme of work combining evidence synthesis, clinical trials, systems pharmacology, statistical modelling, and qualitative methods to optimise how we develop and deploy therapeutic interventions for the world's deadliest - and most neglected - infections.
Her research quality and impact have been recognised by the British Infection Association's Barnett Christie Prize Lecture 2024 and the European Society of Clinical Microbiology and Infectious Diseases' Young Investigator Award 2025.
She is a member of the UK Health Security Agency Malaria Expert Advisory Group and serves on the Editorial Boards of Travel Medicine and Infectious Disease and PLOS Global Public Health.
Xin Hui trained in medicine, infectious diseases, and tropical medicine in Oxford, London (LSHTM & University College London Hospitals), and Southeast Asia with further experience in North America (US National Institutes of Health), West Africa (MRC Unit The Gambia), and Southeastern Europe.
Her UK MRC-funded DPhil with Prof Sir Nick White at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) was a global evidence review of the cardiovascular safety of antimalarial medicines to optimise their development and deployment in collaboration with the WHO Global Malaria Programme. She was the WHO technical resource person and rapporteur of the WHO Evidence Review Group on the Cardiotoxicity of Antimalarial Medicines.
Key publications
-
Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
Sigfrid L. et al, (2025), The Lancet Infectious Diseases
-
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
-
Cardiovascular Concentration‐Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre‐clinical Studies
Chan XHS. et al, (2022), British Journal of Clinical Pharmacology
-
The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis
Chan XHS. et al, (2021), PLOS Medicine, 18, e1003766 - e1003766
-
Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data
Chan XHS. et al, (2020), PLOS Medicine, 17, e1003040 - e1003040
-
The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review
Haeusler IL. et al, (2018), BMC Medicine, 16
-
Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis
Chan XHS. et al, (2018), The Lancet Infectious Diseases, 18, 913 - 923
Recent publications
-
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2025), eClinicalMedicine, 81, 103080 - 103080
-
Multi-antigen serology and a diagnostic algorithm for the detection of arbovirus infections as novel tools for arbovirus preparedness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
Kasbergen LMR. et al, (2025), The Lancet Infectious Diseases
-
Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
Sigfrid L. et al, (2025), The Lancet Infectious Diseases
-
Factors that influence recruitment to COVID-19 vaccine trials: a qualitative evidence synthesis
Biesty L. et al, (2024), Trials, 25
-
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
-
Autochthonous Human Babesia divergens Infection, England
Zabala GA. et al, (2024), Emerging Infectious Diseases, 30
-
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
Faust SN. et al, (2024), The Lancet Child & Adolescent Health, 8, 190 - 200
-
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2023), The Lancet Diabetes & Endocrinology, 11, 905 - 914
-
Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis.
Meskell P. et al, (2023), The Cochrane database of systematic reviews, 9
-
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2023), The Lancet, 401, 1499 - 1507